DFTX (Definium Therapeutics) Accounts Payable: $7.13 Mil (As of Mar. 2026)

What is Definium Therapeutics Accounts Payable?

Definium Therapeutics DFTX +1.07% 32 Accounts Payable is $7.13 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Definium Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $7.13 Mil.

Definium Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($8.11 Mil) to Dec. 2025 ($5.35 Mil) but then increased from Dec. 2025 ($5.35 Mil) to Mar. 2026 ($7.13 Mil).

Definium Therapeutics's annual Accounts Payable declined from Dec. 2023 ($4.14 Mil) to Dec. 2024 ($2.01 Mil) but then increased from Dec. 2024 ($2.01 Mil) to Dec. 2025 ($5.35 Mil).

Definium Therapeutics Accounts Payable Related Terms

Definium Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics Accounts Payable Chart

Definium Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Accounts Payable

Get a 7-Day Free Trial

4.18

2.11

4.14

2.01

5.35

Definium Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Accounts Payable	Get a 7-Day Free Trial															2.27	4.22	8.11	5.35	7.13

32GF Score

Definium Therapeutics Inc DFTX

Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Definium Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →

What does a Accounts Payable of $7.13 Mil mean?

Definium Therapeutics (DFTX) has a Accounts Payable of $7.13 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Definium Therapeutics and its competitors.

Is Definium Therapeutics' Accounts Payable too high?

Definium Therapeutics' current Accounts Payable is $7.13 Mil. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Definium Therapeutics' Accounts Payable compare to LGND and XENE?

Definium Therapeutics' Accounts Payable of $7.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Accounts Payable for a Biotechnology company?

A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Accounts Payable mean?

A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Definium Therapeutics and its competitors. Definium Therapeutics's current Accounts Payable is $7.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Definium Therapeutics stock overvalued right now?

Definium Therapeutics (DFTX) has a current Accounts Payable of $7.13 Mil. The current Accounts Payable is $7.13 Mil. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Accounts Payable calculated?

Accounts Payable is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Accounts Payable is $7.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LGND XENE CGON LEGN TVTX ORKA COGT CRSP SRRK MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MMQ0:Germany

Address One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website https://www.definiumtx.com

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

32GF Score

Get the complete analysis for DFTX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04

Price

View DFTX Analysis

See Accounts Payable data for all stocks →